Cognitive Impairment After Brain Injury
Conditions
Brief summary
This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.
Detailed description
Specific experimental research methods were randomized, controlled, single-center, exploratory clinical study, through the treatment of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment, to observe the effects of their neuroprotection and cognitive function improvement.
Interventions
OTHERMedian nerve electrical stimulation treatment
Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.
intramuscular
DRUGGinkgo leaf dropping pill
oral
Sponsors
Ganzhou City People's Hospital
Wanbangde Pharmaceutical Group Co., LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Be over 18 years old * Residual cognitive impairment due to brain injury * No previous history of brain-related diseases except this one
Exclusion criteria
* The patient had severe underlying disease and unstable vital signs * The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment ③ Allergic to drugs or contraindications in drug use ④ There are contraindications of median nerve electrical stimulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to assess the MMSE score | baseline，Day10，Day90 |
Secondary
| Measure | Time frame |
|---|---|
| to assess the MoCA score | baseline，Day10，Day90 |
| to assess the ADAS-cog score | baseline，Day10，Day90 |
| to assess the HAMD score | baseline，Day10，Day90 |
| to assess the HAMA score | baseline，Day10，Day90 |
Countries
China
Contacts
Primary ContactDong Wang
Outcome results
None listed